Treatment of Von Willebrand Disease (VWD)

Disease Management

• Desmopressin works by stimulating the release of stored VWF from endothelial cells, increasing circulating VWF and factor VIII levels 3-6 fold within 30-90 minutes, with standard intravenous dosing being 0.3 μg/kg (maximum 28 μg) 1
• Doses of desmopressin may be repeated at 12-24 hour intervals, but tachyphylaxis may occur after 3-5 doses due to depletion of endothelial VWF stores 1

Special Clinical Scenarios

• For neuraxial anesthesia in VWD patients, VWF activity levels should be maintained at ≥50 IU/dL, and can be achieved through desmopressin, VWF/FVIII concentrates, or cryoprecipitate, combined with tranexamic acid as appropriate 2, 3
• For patients undergoing surgery, VWF activity should be maintained above 50 IU/dL for the duration of the procedure and postoperative period 2

Acquired Von Willebrand Syndrome (AVWS) Management

• AVWS, particularly in patients requiring extracorporeal membrane oxygenation, requires a multidisciplinary approach, including minimizing anticoagulation and using blood product replacement 1
• For refractory bleeding in AVWS, targeted treatments to restore high molecular weight VWF multimers include desmopressin, VWF-containing concentrates, or drugs that prevent VWF proteolysis 1

Prognosis and Management of von Willebrand Disease

Disease Classification and Severity Spectrum

• The American Journal of Hematology reports that von Willebrand Disease is classified into three main types with varying prognoses, including Type 1, Type 2, and Type 3, which account for ~75% of cases, with typically mild bleeding symptoms, variable bleeding severity, and severe, potentially life-threatening bleeding, respectively 4, 5
• The severity of bleeding symptoms correlates with the type and degree of VWF deficiency, with Type 1 being the mildest and Type 3 being the most severe 4, 5

Clinical Manifestations and Quality of Life

• The American Journal of Hematology states that bleeding following surgery or invasive procedures is a common manifestation of von Willebrand Disease 4
• Central nervous system bleeding is a rare but serious manifestation of von Willebrand Disease 4

Special Considerations

• The prognosis of Acquired von Willebrand Syndrome depends on the underlying condition causing it, and treatment of the underlying disorder may resolve the acquired VWF deficiency 4, 5

Pitfalls in Management

• The use of non-resorbable nasal packing in VWD patients with nosebleeds is a common pitfall to avoid, as recommended by medical guidelines 6

Treatment of Von Willebrand Disease with Emphasis on Acquired Von Willebrand Syndrome

Special Clinical Scenarios

• In patients with Acquired Von Willebrand Syndrome (AVWS), particularly those on ECMO, AVWS develops within hours and persists throughout ECMO support, but resolves rapidly after weaning, according to the Journal of Thrombosis and Haemostasis 7
• Data supporting VWF concentrate use to prevent bleeding in ECMO patients remain limited, highlighting the need for further research in this area, as noted in the Journal of Thrombosis and Haemostasis 7

Acquired von Willebrand Syndrome: Diagnosis and Evaluation

Clinical Presentation

• New‑onset mucocutaneous bleeding in adults without personal or family bleeding history, especially when associated with lymphoproliferative disorders, monoclonal gammopathies, autoimmune diseases, or cardiovascular conditions 8, 9
• Typical bleeding manifestations – easy bruising/ecchymoses, epistaxis, gastrointestinal bleeding, and heavy menstrual bleeding – are common in AVWS patients 9

Distinguishing Features

• Absence of personal and family bleeding history helps differentiate AVWS from hereditary VWD 8, 9
• Presence of an underlying associated condition (e.g., lymphoproliferative, autoimmune, cardiovascular) strongly supports the diagnosis of AVWS 8, 9

Physical Examination Findings

• Ecchymoses, hematomas, petechiae, telangiectasia, and joint/skin laxity may be observed and point toward AVWS in the appropriate clinical context 8

Laboratory Evaluation

• Initial screening panel should include a complete blood count with platelet count, prothrombin time, and activated partial thromboplastin time; however, PT/aPTT alone are insufficient to exclude AVWS 9
• When AVWS is suspected, order VWF antigen, VWF ristocetin cofactor activity, and factor VIII activity simultaneously to assess both quantitative and functional deficits 8, 9
• Low VWF antigen, low VWF activity, and reduced factor VIII levels—mirroring hereditary VWD—are typical laboratory patterns in AVWS 8, 9
• A VWF activity‑to‑antigen ratio < 0.5–0.7 indicates a qualitative defect and should trigger specialized testing (e.g., multimer analysis) 8

Management Pitfalls

• Do not overlook underlying conditions such as lymphoproliferative, autoimmune, or cardiovascular disorders when evaluating a patient with unexplained mucocutaneous bleeding 8

All facts are derived from cited literature and presented in English.